Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0000853 | uM | 10696.154 | 0.9910 | 0.9704 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.000427 | uM | 10696.154 | 0.9729 | 0.9115 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.00213 | uM | 10696.154 | 0.9761 | 0.9219 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0107 | uM | 10696.154 | 0.9667 | 0.8914 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0533 | uM | 10696.154 | 0.9906 | 0.9691 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.267 | uM | 10696.154 | 1.0219 | 1.0726 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 1.33 | uM | 10696.154 | 0.9798 | 0.9340 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 6.67 | uM | 10696.154 | 0.9773 | 0.9257 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 33.3 | uM | 10696.154 | 1.0066 | 1.0219 | 0.6070 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0000853 | uM | 11855.154 | 0.9115 | 0.7256 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.000427 | uM | 11855.154 | 0.8702 | 0.6030 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.00213 | uM | 11855.154 | 0.9736 | 0.9166 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0107 | uM | 11855.154 | 0.9469 | 0.8335 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.0533 | uM | 11855.154 | 0.9934 | 0.9791 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 0.267 | uM | 11855.154 | 0.9169 | 0.7420 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 1.33 | uM | 11855.154 | 0.9330 | 0.7909 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 6.67 | uM | 11855.154 | 0.8880 | 0.6553 | 0.6282 | |
BT-483 | HR+ | Luminal | FTase Inhibitor I | Ftase | MAPK | 33.3 | uM | 11855.154 | 0.8899 | 0.6612 | 0.6282 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.000171 | uM | 12305.167 | 0.9204 | 0.9433 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.000853 | uM | 12305.167 | 1.0248 | 1.0171 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.00427 | uM | 12305.167 | 1.0317 | 1.0218 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.0213 | uM | 12305.167 | 0.9637 | 0.9745 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.107 | uM | 12305.167 | 0.9520 | 0.9661 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 0.533 | uM | 12305.167 | 0.9573 | 0.9699 | 2.8814 | |
BT-549 | TNBC | Basal B | FTase Inhibitor I | Ftase | MAPK | 2.67 | uM | 12305.167 | 0.9719 | 0.9803 | 2.8814 |